Skip to main content
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRDA ISIN · US29384C1080 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2023-11-07 Interim / Quarterly Rep…
Country US United States of America
Listing US TRDA

About Entrada Therapeutics, Inc.

https://www.entradatx.com/

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines to treat devastating diseases. The company's proprietary Endosomal Escape Vehicle (EEV) platform is designed to enable the intracellular delivery of a wide range of therapeutics, allowing access to targets that have historically been considered undruggable. Entrada's development pipeline is concentrated on rare conditions, with programs targeting neuromuscular diseases, including Duchenne muscular dystrophy, as well as ocular diseases. The company's mission is to transform the lives of patients by establishing EEV-based therapeutics as a new treatment modality.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2023
2023-11-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 7, 2023, by Entrada Therapeutics, Inc. It announces the company's financial results for the quarter ended September 30, 2023, and includes a press release as an exhibit. The text explicitly states that the press release is being furnished as Exhibit 99.1 and that the information is intended to be furnished and not filed, indicating this is an announcement of financial results rather than the full financial report itself. The document length is 3718 characters, which is relatively short and consistent with a current report or earnings release announcement rather than a full quarterly or annual report. The key section is "Item 2.02 Results of Operations and Financial Condition," which is typically used for earnings releases or financial results announcements in Form 8-K filings. Therefore, this document is best classified as an Earnings Release (ER) announcement rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2023-11-07 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement. Given the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, but the content is not interpretable as a financial or corporate filing report.
2023-11-01 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes an entry into a material definitive agreement (an amendment to a license agreement and sublicense agreement), milestone payments, and references to exhibits. It does not contain comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It is not a transcript, proxy, or governance document. The document is a regulatory filing announcing material contract amendments and milestone achievements, typical of a Current Report (8-K). Therefore, the best fitting category is Regulatory Filings (RNS). The document length is 6388 characters, which is sufficient for a substantive filing but the content is clearly an 8-K current report, which falls under Regulatory Filings in this classification scheme.
2023-11-01 English
FORM 4
Director's Dealing
2023-10-19 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or changes that shareholders should know about. The content describes Entrada Therapeutics entering into a material definitive agreement for an 'at the market offering' sales agreement to sell shares up to $150 million. It includes details about the sales agreement, the registration statement, and legal opinions. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is clearly an announcement of a capital raising activity and financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just a brief notice or report publication announcement. Confidence is high due to the clear description of the financing transaction and the nature of Form 8-K filings for such events.
2023-09-29 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.